165 related articles for article (PubMed ID: 37142539)
21. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Brezden-Masley C; Yurchenko M; Wylie Q; Douma R; Varu A; Hutton B; Skidmore B; Cameron C
Syst Rev; 2018 Nov; 7(1):191. PubMed ID: 30428932
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant therapy with
Zhu J; Min N; Chen Y; Li X
Ann Transl Med; 2023 Mar; 11(5):200. PubMed ID: 37007556
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer.
Gupta A; Gogia A; Deo S; Sharma DN; Mathur S; Sagiraju HKR
Cancer Treat Res Commun; 2023; 36():100741. PubMed ID: 37453371
[TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
26. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
27. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
28. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
29. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E; Carbognin L; Furlanetto J; Pilotto S; Bonomi M; Guarneri V; Vicentini C; Brunelli M; Nortilli R; Pellini F; Sperduti I; Giannarelli D; Pollini GP; Conte P; Tortora G
Cancer Treat Rev; 2014 Aug; 40(7):847-56. PubMed ID: 24877987
[TBL] [Abstract][Full Text] [Related]
30. Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence.
de Pinho IS; Luz P; Alves L; Lopes-Brás R; Patel V; Esperança-Martins M; Gonçalves L; Freitas R; Simão D; Galnares MR; Fernandes I; Criado SA; Casado SG; Cañada JB; Vega IMS; Costa JG; Fernandes AS; de Sousa RT; Costa L
Clin Drug Investig; 2023 Sep; 43(9):691-698. PubMed ID: 37479867
[TBL] [Abstract][Full Text] [Related]
31. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
32. Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis.
Cai YW; Shao ZM; Yu KD
Front Immunol; 2022; 13():919369. PubMed ID: 35844533
[TBL] [Abstract][Full Text] [Related]
33. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
34. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Villacampa G; Tung NM; Pernas S; Paré L; Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Marín-Aguilera M; Brasó-Maristany F; Waks AG; Pascual T; Martínez-Sáez O; Vivancos A; Conte PF; Guarneri V; Vittoria Dieci M; Griguolo G; Cortés J; Llombart-Cussac A; Muñoz M; Vidal M; Adamo B; Wolff AC; DeMichele A; Villagrasa P; Parker JS; Perou CM; Fernandez-Martinez A; Carey LA; Mittendorf EA; Martín M; Prat A; Tolaney SM
Ann Oncol; 2023 Sep; 34(9):783-795. PubMed ID: 37302750
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Waldron-Lynch M; Eng-Wong J; Kirk S; Cortés J
Eur J Cancer; 2018 Jan; 89():27-35. PubMed ID: 29223479
[TBL] [Abstract][Full Text] [Related]
37. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Shen Y; Fujii T; Ueno NT; Tripathy D; Fu N; Zhou H; Ning J; Xiao L
Breast Cancer Res Treat; 2019 Jan; 173(1):1-9. PubMed ID: 30242579
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
